Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc. has shown promising advancements in the development of therapies for congenital hyperinsulinism, with recent clinical trials indicating a significant reduction in hypoglycemia events among patients, presenting a strong potential for regulatory approval. The company’s Phase 2b RIZE study revealed a 70-90% reduction in weekly hypoglycemia occurrences, supporting the effectiveness of its drug candidates, while safety profiles for treatments like ersodetug were reported as generally favorable. Collaborations with medical communities and ongoing research efforts further strengthen Rezolute's commitment to addressing unmet medical needs, enhancing its outlook for revenue growth and value creation.

Bears say

Rezolute Inc. faces significant challenges following the disappointing Phase 3 trial results for its drug candidate, Ersodetug, which failed to demonstrate a statistically significant benefit compared to placebo, raising concerns about its efficacy and the viability of its treatment approach. The secondary endpoint of the sunRIZE trial regarding hypoglycemia management also fell short, highlighting potential difficulties in conducting clinical trials in an outpatient setting, which could further complicate regulatory approvals and market acceptance. Additionally, the company is exposed to typical industry risks including unforeseen outcomes from clinical trials and increasing complexity in commercial market dynamics, contributing to a negative outlook on its stock.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.